Background: There is limited evidence on optimal assessment and treatment regimens for juvenile localised scleroderma (JLS). The Paediatric Rheumatology European Society (PRES) scleroderma working group has produced consensus recommendations for diagnosis, assessment and management of JLS. We aimed to describe current UK practice with regards to assessment and management of JLS and consider these in the context of PRES working party recommendations. Methods: Patients were eligible if they had a diagnosis of JLS and were under the care of a paediatric rheumatologist between April 2015 and April 2016. Data was collected from eleven UK centres using a standardised proforma. Ethical approval was not required as this was an audit against published standards of care.
Results: 149 patients were included with a mean age at time of audit of 12.1 years and 7.6 years at time of diagnosis. Patients had a variety of disease subtypes: 67.1% linear scleroderma; 14.8% plaque morphoea; 10.1% generalised morphoea; 1.3% pansclerotic disease; 6.7% mixed disease. 16.1% (24/149) had extracutaneous manifestations including three (2.0%) with uveitis and two (1.3%) with CNS vasculitis. UK practice is not consistently in line with PRES working party recommendations (Table 1) . Screening for extracutaneous manifestations was varied. Recommendations include that patients with craniofacial involvement have regular screening for uveitis and an MRI brain. Of patients with craniofacial involvement (n ¼ 52), only 38.5% were ever screened for uveitis with only one patient receiving six monthly screening. 37 (71.2%) of these patients had MRI imaging. Standardised outcome measures were only used in 83/149 (55.7%). Systemic immunosuppressive treatment was widely used (96.0%) and met standards of care in all patients. 95.5% received methotrexate as first line therapy. 34.2% required two or more sequential immunosuppressants and 86.0% received systemic corticosteroids highlighting the significant treatment burden. Conclusion: Although there is a consistent approach to systemic treatment within UK paediatric rheumatology, there is wide variation in assessment and screening of JLS patients. Improved awareness of these recommendations is required to ensure standardised care. As these recommendations are based on low level evidence and consensus opinion, further studies are needed to better define outcome and treatment regimens. Disclosures: D.H. has received honoraria from Pfizer, Abbvie, and Roche-Chugai. V.L. has received honoraria from Abbvie. E.H., H.L., B.A., J.B., C.B., A.B., M.B., S.D., P.D., D.E., E.L., S.M., F.M., N.R., A.R., P.R., R.S., K.H., and C.E.P. have declared no conflicts of interest. Results: Renal involvement was seen in 64 patients (20.4%) after a mean duration of 32.3 days from the onset of symptoms of HSP. Renal manifestations developed in 57.8% of the patients within four weeks of symptom onset, in 84.4% within eight weeks and in 100% within six months. Massive proteinuria was the most common clinical feature (56.7%) followed by minimal proteinuria (21.7%), moderate proteinuria (15%) and isolated hematuria (6.7%). Hypertension was seen in 24 patients. Four patients had deranged renal function tests.13 patients developed a clinical relapse of the renal disease after a mean interval of 551.5 days from the remission of first episode. Albuminuria with microscopic hematuria was the most common presentation of second episode (77%) followed by isolated albuminuria (23%). Kidney biopsy was done in 48 patients. Three fourth of the patients had histological grade II or IIIa. 75% of patients with grade ! IV had gross hematuria at presentation. 25 patients received prednisolone alone, 31 received azathioprine in addition to prednisolone, while cyclophosphamide and mycophenolate mofetil were used in five and one patient respectively. Patients were followed up for a mean period of 3.6 years during which 13 were lost to follow up, one expired while three patients each are currently on prednisolone and azathioprine. Nephritis resolved in 48 patients (75%) with mean duration of renal involvement being more in patients with nephritis at presentation (429 days) as compared to patients who develop nephritis in follow up (321 days Background: Although biosimilar drugs are increasingly use in adults, there is little to no data available on their use in juvenile idiopathic arthritis (JIA). This analysis aims to describe the characteristics of children and young people (CYP) with JIA starting biosimilars in the UK over the first two years following their approval in the United Kingdom (UK) for adults with musculoskeletal diseases. Methods: The Biologics for Children with Rheumatic diseases (BCRD) study, launched in 2010, is an ongoing prospective UK study of children with JIA starting biologic therapies other than etanercept (followed in a separate parallel study). Baseline information is collected via questionnaires completed by the treating physician or affiliated clinical research nurse. Follow-up data including disease activity measures and changes in drug therapy are collected at six months, one year and annually thereafter. Since 30/09/2015, data has been captured on three biosimilars available in the UK: infliximab (inflectra and remsima) and etanercept (benepali). Results: To 10/05/2017, 26 patients were identified in the BCRD study starting a biosimilar: 21 (81%) remsima, 3 (12%) Inflectra and two (8%) benepali). Of these, 9 (35%) started a biosimilar as their first biologic therapy. Only one patient starting remsima switched directly from the originator product, remicade. Sixteen (62%) switched from an alternative non-originator biologic (Table 1) . Reasons for switching from these alternative biologics were efficacy reasons (n ¼ 8, 50%), safety reason (n ¼ 5, 31%), efficacy and safety issues combined (n ¼ 2, 13%) and needle phobia (n ¼ 1, 6%). Six-month and one year followup data were available in three and one CYP respectively. No serious adverse events have been reported to date and all four CYP continue on their biosimilar drug. Conclusion: This preliminary study gives a first overview of initial biosimilar use in CYP with JIA in the UK. These drugs are used as both first-line and subsequent-line biologic therapy despite a lack of license for this indication. Unlike evidence from rheumatoid arthritis, where a majority of patients receiving biosimilars to date have switched from the originator, this initial experience in JIA suggests that biosimilars are being considered as front line therapeutic option instead of the originator, presumably as a cost-saving measure. Disclosures: The authors have declared no conflicts of interest.
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